Telitacicept for the Treatment of Refractory RA

Sponsor
Chinese SLE Treatment And Research Group
Study ID
NCT07008196
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Rheumatoid Arthritis (RA)

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Telitacicept — DRUG
    Telitacicept 160mg qw subcutaneous injection

Study Details

This is a single-center, single-arm, open-label, prospective study on the efficacy and safety of Telitacicept in patients with refractory rheumatoid arthritis.

Key Dates

Start date
Jun 10, 2025
Status verified
Jun 2025
Primary completion
Dec 31, 2025
Completion
Jan 31, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Telitacicept treatment group
    Telitacicept added on previous treatment

Primary Outcome Measure

ACR20 at week 12 [ Time Frame: Week 12 ]

Central Contacts

Related Studies